OVARIAN DYSGERMINOMAS: TREATMENT EXPERIENCE OF THE N.N.BLOKHIN CRC RAMS
https://doi.org/10.17650/1994-4098-2008-0-1-52-56
Abstract
This is a retrospective review of treatment results of 35 patients with dysgerminomas in the Departments of Clinical Pharmacology and Gynecology, N.N.Blokhin Russian Cancer Research Center (NNBRCRC) between 1990 and 2006.
Primary surgery was carried out in all patients. Twenty patients (57%) underwent fertility-sparing surgery. Postoperative systemic chemotherapy was administered to 28 (80%) women: аmong them 23 received platinum-based chemotherapy, 5 were treated with non- platinum combinations.
At a median follow-up of 75 months the disease-free survival was 71,4% and the overall survival was 97,1%. Our data confirmed that prog- nosis of dysgerminomas is excellent if managed with standard treatment initially, this is possible, as a rule, only in specialized cancer centers.
About the Authors
O. N. Streltzova
N.N. Blokhin Cancer Research Center of Russian Academy of Medical Sciences , Moscow
Russian Federation
Russian Federation
M. Yu. Fedyanin
N.N. Blokhin Cancer Research Center of Russian Academy of Medical Sciences , Moscow
Russian Federation
Russian Federation
A. A. Tryakin
N.N. Blokhin Cancer Research Center of Russian Academy of Medical Sciences , Moscow
Russian Federation
Russian Federation
A. A. Bulanov
N.N. Blokhin Cancer Research Center of Russian Academy of Medical Sciences , Moscow
Russian Federation
Russian Federation
V. V. Zhordania
N.N. Blokhin Cancer Research Center of Russian Academy of Medical Sciences , Moscow
Russian Federation
Russian Federation
S. A. Tyulandin
N.N. Blokhin Cancer Research Center of Russian Academy of Medical Sciences , Moscow
Russian Federation
Russian Federation
References
1. Quirk J.T., Natarajan N. Ovarian cancer incidence in the United States, 1992— 1999. Gynecol Oncol 2005;97:519—523.
2. Тюляндин С.А. Герминогенные опухоли яичников. Практ онкол 2006;7(1).
3. Козаченко В.П. Клиническая онкогинекология. Руководство для врачей. М., Медицина; 2005. с. 247— 253.
4. Patterson D.M., Rustin G.J. Controversies in the management of germ cell tumors of the ovary. Curr Opin Oncol 2006;18:500—506.
5. Norris H.J., Jensen R.D. Relative fre- quency of ovarian neoplasms in children and adolescents. Cancer 1972;30:713— 719.
6. Brewer M., Gershenson D.M., Herzog C.E. et al. Outcome and repro- ductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol 1999;17:2670—2675.
7. Lawrence M.R., Talerman A. Recent Advances in the Pathology and Classification Of Ovarian Germ Cell Tumors. Int J of Gynecol Pathology 2006;25:305—320.
8. Kurman R.J., Norris H.J. Malignant mixed germ cell tumors of the ovary. A clinical and pathologic analysis of 30 cases. Obstet Gynecol 1976;48:579—589.
9. Kurman R.J., Norris H.J. Malignant germ cell tumors of the ovary. Hum Pathol 1977;8:551—564.
10. You W., Dainty L.A., Rose G.S. et al. Gynecologic malignancies in women aged less than 25 years. Obstet Gynecol 2005;105:1405—1409.
11. Deligeoroglou E., Eleftheriades M., Shiadoes V. et al. Ovarian masses during adolescence: clinical, ultrasonographic and pathologic findings, serum tumor markers and endocrinological profile. Gynecol Endocrinol 2004;19:1—8.
12. Bridgewater J.A., Rustin G.J. Management of nonepithelial ovarian tumours. Oncology 1999;57:89—98.
13. Hurteau J.A., Williams S.J. Ovarian germ cell tumours. Ovarian. Cancer, 2 edn. Rubin S.C., Sutton G.P. (eds). Philadelphia, Lippincott Williams & Wilkins; 2001. p. 373—382.
14. Dark G.G., Bower M., Newlands E.S. Surveillance policy for stage I ovarian germ cell tumours. J Clin Oncol 1997; 15:620—624.
15. Einhorn L.H., Donohue J. Cis- diamminedichloroplatinum, vinblastine, and bleomycin combination chemothera- py in disseminated testicular cancer. Ann Intern Med 1977;87:293—298.
16. Gershenson D.M., Morris M., Cangir A. et al. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J Clin Oncol 1990;8:715—720.
17. Williams S., Blessing J.A., Liao S.Y. et al. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin. A trial of the Gynecologic Oncology Group. J Clin Oncol 1994;12:701—706.
18. Gershenson D.M., Wharton J.T., Kline R.C. et al. Chemotherapeutic com- plete remission in patients with metastat- ic ovarian dysgerminoma. Potential for cure and preservation of reproductive capacity. Cancer 1986;58:2594—2599.
19. Williams S.D., Blessing J.A., Hatch K.D. et al. Chemotherapy of advanced dysgerminoma: Trials of the Gynecologic Oncology Group. J Clin Oncol 1991;9:1950—1955.
20. Williams S.D., Kauderer J., Burnett A.F. et al. Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide. A trial of the Gynecologic Oncology Group. Gynecol Oncol 2004;95: 496—499.
21. Gershenson D.M. Fertility-sparing surgery for malignancies in women. J Natl Cancer Inst Monogr 2005; 34:43—47.
22. Zanetta G., Bonazzi C., Cantu M. et al. Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol 2001; 19:1015—1020.
23. Zanagnolo V., Sartori E., Trussardi E. et al. Preservation of ovarian function, reproductive ability and emotional atti- tudes in patients with malignant ovarian tumors. Eur J Obstet Gynecol Reprod Biol 2005; 123:235—243.
24. Serov S.F., Scully R.E., Sobin L.H. Histological typing of ovarian tumours. International histological classification of tumours, No. 9, Geneva, World Health Organization; 1973.
25. Raghavan D. Atlas of Clinical Oncology. Germ Cell Tumors. London; 2003. p. 39.
26. Zanagnolo V., Sartori E., Galleri G. et al. Clinical review of 55 cases of malig- nant ovarian germ cell tumors. Eur J Gynaecol Oncol 2004; 25:315—320.
27. Billmire D., Vinocur C., Rescorla F. et al: Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: An intergroup study. J Pediatr Surg 2004;39:424—429.
28. Gobel U., Schneider D.T., Calaminus G. et al. Germ-cell tumors in childhood and adolescence: GPOH MAKEI and the MAHO study groups. Ann Oncol 2000;11:263—271.
29. Lai C.H., Chang T.C., Hsueh S. et al. Outcome and prognostic factors in ovari- an germ cell malignancies. Gynecol Oncol 2005;96:784—791.
30. Murugaesu N., Schmid P., Dancey G. et al. Malignant ovarian germ cell tumors. Identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol 2006;24:4862—4866.
31. Bower M., Fife K., Holden L. et al. Chemotherapy for ovarian germ cell tumours. Eur J Cancer 1996;32A:593—597.
32. Newlands E.S., Bower M., Holden L. et al. Management of Stage I and metasta- tic ovarian germ cell tumors (OGCT). Proc ASCO 1996;15:A774 (abstr.).
33. Slayton R.E., Park R.C., Silverberg S.G. et al. Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary. A Gynecologic Oncology Group Study (a final report). Cancer 1985;56:243—248.
34. Williams S.D., Blessing J.A., Moore D.H. et al. Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ-cell tumors. A trial of the Gynecologic Oncology Group. Ann Intern Med 1989;111:22—27.
35. Scully R.E., Sobin L.H. Histological Typing of Ovarian Tumours. World Health Organization International Histological Classification of Tumours (ed 2). Berlin, Germany, Springer; 1999.
36. Leiserowitz G.S., Xing G., Cress R. et al. Adnexal masses in pregnancy: how often are they malignant? Gynecol Oncol 2006;1001:315—321.
Review
For citations:
Streltzova O.N., Fedyanin M.Yu., Tryakin A.A., Bulanov A.A., Zhordania V.V., Tyulandin S.A. OVARIAN DYSGERMINOMAS: TREATMENT EXPERIENCE OF THE N.N.BLOKHIN CRC RAMS. Tumors of female reproductive system. 2008;(1):52-56. (In Russ.) https://doi.org/10.17650/1994-4098-2008-0-1-52-56
Views:
412
Email this article 